Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
October 14, 2024 09:05 ET
|
Longeveron
Longeveron Lomecel-B data in Alzheimer's disease selected for late breaking poster presentation at Clinical Trials on Alzheimer’s Disease Conf (CTAD24).
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
October 07, 2024 09:05 ET
|
Longeveron
Wa’el Hashad, Chief Executive Officer of Longeveron, will participate in a Fireside Chat at the UBS Virtual Organ Restoration and Cell Therapy Day Oct 15th
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 02, 2024 09:05 ET
|
Longeveron
Longeveron management to present at the ROTH Healthcare Opportunities Conference. Speaking on Emerging Frontiers in Neuroscience panel and hosting 1x1s.
Adaptive Research Announces it has Begun Enrolling Patients in AriBio’s Phase 3 POLARIS-AD Clinical Trial
September 30, 2024 08:00 ET
|
Adaptive Research Inc
Adaptive Research announced it has begun enrolling patients in
AriBio’s Phase 3 POLARIS-AD Clinical Trial.
Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
September 26, 2024 09:05 ET
|
Longeveron
Longeveron to attend Cell & Gene Meeting on the Mesa to highlight its cellular therapy program in Alzheimer's disease and CDMO facilities and services.
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
August 26, 2024 16:05 ET
|
Longeveron
Longeveron to present at HC Wainwright global investment conference.
Author Sonya Jury Shares Life Lessons in Her New Book Mom Forgot My Birthday: A Daughter’s Journey Through Alzheimer’s
August 26, 2024 07:00 ET
|
Sonya Jury, Author
Sonya Jury shares her lessons as a caregiver in her book, "Mom Forgot My Birthday: A Daughter’s Journey Through Alzheimer’s."
Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024 16:05 ET
|
Longeveron
Longeveron reports Q2 2024 financial results and provides business update. Phase 2b clinical trial in HLHS achieves 70% enrollment.
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
August 14, 2024 08:30 ET
|
Vaccinex, Inc.
Company reviews goals and significance of the clinical trial and outlines development and partnering strategy
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024 09:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - According to a report from Mordor Intelligence, the Alzheimer's Disease Diagnostics And Therapeutics Market size...